相关参考文献
注意：仅列出部分参考文献，下载原文获取全部文献信息。Effect of renin-angiotensin-aldosterone system triple blockade on non-diabetic renal disease: Addition of an aldosterone blocker, spironolactone, to combination treatment with an angiotensin-converting enzyme inhibitor and angiotensin II receptor blocker
Yoshiyuki Furumatsu et al.
HYPERTENSION RESEARCH (2008)
Renal injury due to renin-angiotensin-aldosterone system activation of the transforming growth factor-β pathway
G. Wolf
KIDNEY INTERNATIONAL (2006)
Long-term effects of spironolactone on proteinuria and kidney function in patients with chronic kidney disease
S. Bianchi et al.
KIDNEY INTERNATIONAL (2006)
Aldosterone blockade: An emerging strategy for abrogating progressive renal disease
Murray Epstein
AMERICAN JOURNAL OF MEDICINE (2006)
Beneficial impact of spironolactone on nephrotic range albuminuria in diabetic nephropathy
K. J. Schjoedt et al.
KIDNEY INTERNATIONAL (2006)
Effect of low-dose dual blockade of renin-angiotensin system on urinary TGF-β in type 2 diabetic patients with advanced kidney disease
JH Song et al.
NEPHROLOGY DIALYSIS TRANSPLANTATION (2006)
Accurate measurement and clinical significance of urinary transforming growth factor-beta
Sotiris Tsakas et al.
AMERICAN JOURNAL OF NEPHROLOGY (2006)
Aldosterone blockage in proliferative glomerulonephritis prevents not only fibrosis, but proliferation as well
Mustafa Gullulu et al.
RENAL FAILURE (2006)
Antagonists of aldosterone and proteinuria in patients with CKD: An uncontrolled pilot study
S Bianchi et al.
AMERICAN JOURNAL OF KIDNEY DISEASES (2005)
Renal protective effects of the renin-angiotensin-aldosterone system blockade: From evidence-based approach to perspectives
L Tylicki et al.
KIDNEY & BLOOD PRESSURE RESEARCH (2005)
Excerpts from the United States Renal Data System 2004 Annual Data Report: Atlas of end-stage renal disease in the United States - Perface
AJ Collins et al.
AMERICAN JOURNAL OF KIDNEY DISEASES (2005)
Review of aldosterone- and angiotensin II-induced target organ damage and prevention
AD Struthers et al.
CARDIOVASCULAR RESEARCH (2004)
Urinary transforming growth factor-β1 in various types of nephropathy
P De Muro et al.
PHARMACOLOGICAL RESEARCH (2004)
Additive effects of combined valsartan and spironolactone on cardiac aldosterone escape in spontaneously hypertensive rats
YH Liang et al.
LIFE SCIENCES (2004)
Aldosterone in the development and progression of renal injury
NK Hollenberg
KIDNEY INTERNATIONAL (2004)
Effect of losartan and amlodipine on proteinuria and transforming growth factor-β1 in patients with IgA nephropathy
HC Park et al.
NEPHROLOGY DIALYSIS TRANSPLANTATION (2003)
Therapeutic benefit of spironolactone in experimental chronic cyclosporine A nephrotoxicity
I Feria et al.
KIDNEY INTERNATIONAL (2003)
Aldosterone breakthrough during angiotensin II receptor antagonist therapy in stroke-prone spontaneously hypertensive rats
M Naruse et al.
HYPERTENSION (2002)
Proteinuria and tubulointerstitial lesions in lupus nephritis
GS Hill et al.
KIDNEY INTERNATIONAL (2001)
Spironolactone in addition to ACE inhibition to reduce proteinuria in patients with chronic renal disease.
A Chrysostomou et al.
NEW ENGLAND JOURNAL OF MEDICINE (2001)
Aldosterone escape during angiotensin-converting enzyme inhibitor therapy in essential hypertensive patients with left ventricular hypertrophy
A Sato et al.
JOURNAL OF INTERNATIONAL MEDICAL RESEARCH (2001)
Urinary transforming growth factor-β1 and α1-microglobulin in children and adolescents with type 1 diabetes
E Korpinen et al.
DIABETES CARE (2000)
分享论文
